Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

Dong-A ST's biosimilar product Imuldosa has been approved by the U.S. Food and Drug Administration (FDA), the Korean ...

Rheumatoid arthritis: An autoimmune condition where the immune system attacks the joints. • Gout: Caused by the accumulation ...

Arthritis is a chronic inflammatory condition that affects the joints, causing swelling, pain, and stiffness. It is one of ...

Treatment for arthritis is mainly focused on symptom management and slowing the progression of the disease, says Dr Vishal ...

Lifestyle changes become critical components of arthritis management. An appropriate diet, low-impact exercise, and ...

Arthritis, often thought to be an ailment of the elderly, is an autoimmune disease prevalent across all ages, particularly in ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.